Atara Biotherapeutics, Inc.: Atara Biotherapeutics to Receiv

Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines

Related Keywords

California , United States , South San Francisco , Pierre Fabre , Eric Hyllengren , Alex Chapman , Eric Ducournau , Pascal Touchon , Atara Biotherapeutics Inc , Linkedin , Twitter , European Commission , Drug Administration , Nasdaq , Exchange Commission , European Medicines Agency , Securities Exchange , Million Upon European Commission Ec Approval , Receive Additional , Upon European Commission , Authorization Transfer , Final Day , Marketing Authorization Application , Middle East , Breakthrough Therapy Designation , Priority Medicines , Securities Act , Securities Exchange Act , Southern California , Financial Condition , Katara , Iotherapeutics , Eceive , Dditional , Ear , Term , Milestone , Payment , Under , Pdated , Tabelecleucel , Ommercialization , Agreement , Pierre , Sabre ,